Clover Biopharmaceuticals, Ltd. (2197.HK)
HKD 0.26
(0.0%)
HKD 0.26
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 39.25 Million | - | - | - | - |
| Cost of Revenue | 15.01 Million | 475.64 Million | 66.26 Million | - | - |
| Gross Profit | 24.24 Million | -475.64 Million | -66.26 Million | - | - |
| Operating Expenses | 24.24 Million | 1.86 Billion | 2.15 Billion | 284.28 Million | 46.92 Million |
| Selling, General and Administrative Expenses | 107.24 Million | 113.07 Million | 345.71 Million | 76.42 Million | 17.03 Million |
| Research and Development Expenses | 649.88 Million | 1.46 Billion | 1.82 Billion | 228.21 Million | 45.79 Million |
| Other Expenses | -732.88 Million | 282.75 Million | -14.22 Million | -20.35 Million | -15.9 Million |
| Cost and Expenses | 39.25 Million | 1.86 Billion | 2.15 Billion | 284.28 Million | 46.92 Million |
| Operating Income | - | -2.44 Billion | -6.01 Billion | -909.92 Million | -38.25 Million |
| Interest Expense | 18.72 Million | 5.93 Million | 2.52 Million | 2.97 Million | 10.33 Million |
| Income Tax Expense | - | -229 Thousand | 1.61 Million | 2.97 Million | 10.33 Million |
| Earnings before Tax | -138.53 Million | -2.45 Billion | -6.01 Billion | -912.89 Million | -48.58 Million |
| Net Income | -138.53 Million | -2.45 Billion | -6.01 Billion | -915.87 Million | -58.91 Million |
| Earnings Per Share Basic | -0.11 | -2.22 | -13.02 | -0.79 | -0.05 |
| Earnings Per Share Diluted | -0.11 | -2.22 | -13.02 | -0.79 | -0.05 |
| Weighted Average Shares Outstanding | 1.24 Billion | 1.1 Billion | 462.11 Million | 1.15 Billion | 1.15 Billion |
| Weighted Average Shares Outstanding (Diluted) | 1.24 Billion | 1.1 Billion | 462.11 Million | 1.15 Billion | 1.15 Billion |
| Gross Margin | 0.62 | - | - | - | - |
| EBIT Margin | -1.15 | - | - | - | - |
| Profit Margin | -3.53 | - | - | - | - |
| EBITDA | -45.07 Million | -2.38 Billion | -2.22 Billion | -335.04 Million | -61.76 Million |
| Earnings Before Tax Margin | - | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | -5.05 Million | -5.05 Million | 39.25 Million | 19.49 Million | 19.49 Million | 128.5 Thousand |
| Cost of Revenue | 79 Thousand | 79 Thousand | 15.01 Million | 237.75 Million | 237.75 Million | 618.45 Million |
| Gross Profit | -5.12 Million | -5.12 Million | 24.24 Million | -218.25 Million | -218.25 Million | -618.32 Million |
| Operating Expenses | 73.52 Million | 73.52 Million | 896.33 Million | 192.94 Million | 175.98 Million | 944.6 Million |
| Selling, General and Administrative Expenses | 24.37 Million | 24.37 Million | - | 60.8 Million | 60.8 Million | 65.98 Million |
| Research and Development Expenses | 49.14 Million | 49.14 Million | - | 132.14 Million | 132.14 Million | 192.8 Million |
| Other Expenses | - | - | 2.53 Billion | - | - | -1.39 Billion |
| Cost and Expenses | 73.6 Million | 73.6 Million | 911.34 Million | 430.69 Million | 413.74 Million | 1.56 Billion |
| Operating Income | -78.65 Million | -78.65 Million | -2.6 Billion | -411.2 Million | -420.36 Million | -880.24 Million |
| Interest Expense | - | - | 18.72 Million | - | - | 13.28 Million |
| Income Tax Expense | -90.5 Thousand | -90.5 Thousand | 4.24 Billion | -9.16 Million | - | 3.00 |
| Earnings before Tax | -47.56 Million | -47.56 Million | -138.53 Million | -394.58 Million | -394.58 Million | 325.31 Million |
| Net Income | -47.56 Million | -47.56 Million | -138.53 Million | -394.58 Million | -394.58 Million | 325.31 Million |
| Earnings Per Share Basic | -0.04 | -0.04 | - | -0.32 | -0.32 | 0.26 |
| Earnings Per Share Diluted | -0.04 | -0.04 | - | -0.32 | -0.32 | 0.26 |
| Weighted Average Shares Outstanding | 1.18 Billion | 1.18 Billion | 1.24 Billion | 1.24 Billion | 1.24 Billion | 1.25 Billion |
| Weighted Average Shares Outstanding (Diluted) | 1.25 Billion | 1.25 Billion | 1.24 Billion | 1.24 Billion | 1.24 Billion | 1.24 Billion |
| Gross Margin | 1.02 | 1.02 | 0.62 | -11.19 | -11.19 | -4811.86 |
| EBIT Margin | 13.80 | 13.80 | - | -21.02 | -21.02 | -6782.80 |
| Profit Margin | 9.42 | 9.42 | -3.53 | -20.24 | -20.24 | 2531.61 |
| EBITDA | -69.71 Million | -69.71 Million | - | -409.86 Million | -409.86 Million | -871.58 Million |
| Earnings Before Tax Margin | 15.58 | 15.58 | -66.47 | -21.09 | -21.56 | -6850.14 |
STAOF
3753
002749
VVV
CBRI
6560